The beneficial role of Asian-based RecurIndex test in the prognostic prediction in Chinese male breast cancer patients

Abstract

RecurIndex, a multigene profiling assay, can predict the risk of local recurrence and distant metastasis in female breast cancer (FBC), but its role in male breast cancer (MBC) remains unclear. In this study, the clinicopathological data of 43 consecutive MBC patients undergoing surgeries between 2009 and 2018 were retrospectively analysed. Their paraffin-embedded tissue sections were examined by RecurIndex test which comprised 2 models: recurrence index for local recurrence (RI-LR) and recurrence index for distant recurrence (RI-DR). Of 43 patients, there were 26 low-risk and 17 high-risk patients assessed by RI-LR, while 17 low-risk and 26 high-risk patients by RI-DR. For RI-LR, tumor N stage showed statistically significant (P < 0.001) between low- and high-risk patients; for RI-DR, differences were pronounced in tumor grade (P = 0.033), T stage (P = 0.043) and N stage (P = 0.003). In terms of clinical outcomes, the overall survival (OS) of low- and high-risk patients stratified by RI-LR showed no statistically significant differences (P = 0.460), while high-risk patients identified by RI-DR had a significantly worse distant recurrence-free survival (DRFS) (P = 0.035), progression-free survival (PFS) (P = 0.019) and OS (P = 0.044) than low-risk patients. Overall, RI-DR can effectively predict the DRFS, PFS and OS of MBC patients and identify those at low risk of recurrence, which may serve as a potential prognostic tool for MBC.

Clinicopathological features of male patients with breast cancer based on a nationwide registry database in Japan

“…Additionally, similar to previous findings, MBC was more likely to be hormone receptor positive and less likely to be HER2 positive than FBC (Table S2b). The luminal subtype was the most common at 87.8%, which is consistent with previous reports [ 4 , 23 ]. The frequency of the HER2-type and TNBC was slightly higher in our study than that of previous reports, suggesting that the biology may be different in Europe and the United States than in Japan [ 4 , 23 – 25 ].…”

“…The luminal subtype was the most common at 87.8%, which is consistent with previous reports [ 4 , 23 ]. The frequency of the HER2-type and TNBC was slightly higher in our study than that of previous reports, suggesting that the biology may be different in Europe and the United States than in Japan [ 4 , 23 – 25 ]. A positive family history of breast cancer was more common in FBC, while family history tended to be unknown in MBC cases (Table S3).…”

RecurIndex assay as an aid for adjuvant chemotherapy decisions in HR-positive HER2-negative breast cancer patients

“…Statistically significant differences were shown between the low- and high-risk patients regarding age, tumor stage, histological grade and LVI, highlighting the correlation between RecurIndex assay and these clinicopathological features previously confirmed to be able to assess the risk of breast cancer ( 20 – 22 ). Moreover, low-risk patients harbored a decreased risk of recurrence and metastasis and better 7-year RFS, DRFS and LRFS rates compared with high-risk patients, suggesting the accuracy of RecurIndex assay in risk stratification of patients and its importance as a promising complementary tool to be predictive of prognosis, in agreement with recent findings ( 11 , 23 , 24 ). Of note, adjuvant chemotherapy did not improve the survival outcomes of low-risk patients, offering clinicians an opportunity to identify the patients at low risk for whom chemotherapy can be omitted to avoid treatment-related toxicities.…”

Is it beneficial for patients with pT1‐2N1M0 breast cancer to receive postmastectomy radiotherapy? An analysis based on RecurIndex assay

“…The primer pairs of genes included in RecurIndex assay were complementary to the messenger RNA sequence of each target gene, and PanelStation was used for real‐time fluorescent quantitative amplification. Based on gene‐expression profiling of breast cancer and clinical factors, the risk scores of LRR and distant recurrence were calculated using analysis software 13 …”

“…Based on gene-expression profiling of breast cancer and clinical factors, the risk scores of LRR and distant recurrence were calculated using analysis software. 13…”